Screener
Amylyx Pharmaceuticals, Inc. AMLX Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:04 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336682
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Withholding taxes paid on stock-based awards | (4,436) | (988) |
| Net cash provided by financing activities | 4,696 | 65,631 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash equivalents | (179) | 805 |
| Net decrease in cash, cash equivalents and restricted cash equivalents | (177,324) | (19,301) |
| Cash, cash equivalents and restricted cash equivalents, beginning of period | 227,636 | 78,837 |
| Cash, cash equivalents and restricted cash equivalents, end of period | $50,312 | $59,536 |
| Reconciliation of cash, cash equivalents and restricted cash equivalents: | ||
| Cash and cash equivalents | $49,326 | $58,085 |
Item 1. Financial Statements.
FAQ
- What is Amylyx Pharmaceuticals, Inc.'s net change in cash?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported net change in cash of -$179.81M in Q2 2026.
- How has Amylyx Pharmaceuticals, Inc.'s net change in cash changed year-over-year?
- Amylyx Pharmaceuticals, Inc.'s net change in cash decreased by 10622.1% year-over-year, from -$1.68M to -$179.81M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Amylyx Pharmaceuticals, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude